Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Biochim Biophys Sin (Shanghai) ; 54(3): 400-408, 2022 Mar 25.
Article in English | MEDLINE | ID: mdl-35538033

ABSTRACT

Tetraspanin CD82 often participates in regulating the function of epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met). Palmitoylation is a post-translational modification that contributes to tetraspanin web formation and affects tetraspanin-dependent cell signaling. However, the molecular mechanisms by which CD82 palmitoylation affects the localization and stability of EGFR and c-Met have not yet been elucidated. This study focuses on the expression and distribution of EGFR and c-Met in breast cancer as well as the related metabolic pathways and molecular mechanisms associated with different CD82 palmitoylation site mutations. The results show that CD82 with a palmitoylation mutation at Cys5+Cys74 can promote the internalization of EGFR. EGFR is internalized and strengthened by direct binding to CD82 with the tubulin assistance and located at the recycling endosome. After studying the recycling pathway marker proteins Rab11a and FIP2, we found that formation of the EGFR/CD82/Rab11a/FIP2 complex promotes the internalization and metabolism of EGFR through the recycling pathway and results in the re-expression of EGFR and CD82 on the cell membrane.


Subject(s)
Kangai-1 Protein , Lipoylation , ErbB Receptors/genetics , ErbB Receptors/metabolism , Kangai-1 Protein/genetics , Kangai-1 Protein/metabolism , Mutation , Phosphorylation
2.
Mol Carcinog ; 58(5): 674-685, 2019 05.
Article in English | MEDLINE | ID: mdl-30604894

ABSTRACT

CD82, a member of the tetraspanin superfamily, has been proposed to exert its activity via tetra-transmembrane protein enriched microdomains (TEMs) in exosomes. The present study aimed to explore the potential of the exosome protein CD82 in diagnosing breast cancers of all stages and various histological subtypes in patients. The results strongly suggest that CD82 expression in breast cancer tissue was significantly lower than that in healthy and benign breast disease tissues. There was a significant negative correlation between CD82 expression in tissues and CD82 content in exosomes, which indicated that CD82 expression was redistributed from tissues to the blood with the development and metastasis of breast cancer.


Subject(s)
Adenocarcinoma, Mucinous/diagnosis , Biomarkers, Tumor/metabolism , Breast Neoplasms/diagnosis , Carcinoma, Ductal, Breast/diagnosis , Carcinoma, Lobular/diagnosis , Exosomes/metabolism , Kangai-1 Protein/metabolism , Adenocarcinoma, Mucinous/metabolism , Adult , Aged , Breast Neoplasms/metabolism , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Lobular/metabolism , Case-Control Studies , Feasibility Studies , Female , Follow-Up Studies , Humans , Middle Aged , Precision Medicine , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...